Intensifying Competition, Lower Prices and Loss of Existing Market Share
First written in FY2024. 2 of 5 entries say "Worsened", first in 2026-05-14. Latest entry: FY2026.
TAUNS Laboratories moved to the "Worse" side of this theme in 2026, 7 years after the typical company in this theme (2019).
The whole theme swung hardest in 2026: 41 of 86 companies on the "Worse" side.
5 other companies' latest entry also says "Other".
- FY2026Updated market growth forecastAnnual report
「According to IMARC Group's “Point of Care Molecular Diagnostics Market Report 2026-2034,” the global point-of-care testing (POCT) market, which is our target market, is forecast to grow at a CAGR of 8.09% from 2026 to 2034.」
The market growth forecast was updated from 2025-2033 and a CAGR of 7.6% to 2026-2034 and a CAGR of 8.09%. References to the clinical laboratory services market and point-of-care molecular diagnostic systems were also added. - FY2025Updated market growth forecastAnnual report
「According to IMARC Group’s Point-of-Care Diagnostics Market Report 2025-2033, the global market for point-of-care testing (POCT), our target market, is forecast to grow at a CAGR of 7.6% from 2025 to 2033 (US$53.1 billion in 2025 and US$102.4 billion in 2033).」
The forecast period, growth rate, and projected market size for the market environment and competition risk have been updated. The company continues to state that price-focused products are being introduced. - FY2024First statedAnnual report
「Recently, overseas manufacturers and domestic late entrants have been introducing products that emphasize price.」
While citing a forecast that the global POCT market would grow at a CAGR of 9.4% from 2023 to 2028, from US$49.7 billion to US$77.8 billion, the company identifies intensifying competition as a risk.